New compounds targeting Alzheimer’s disease offered for licensing
A research team composed by researchers from three Spanish Universities has developed a new family of I2 Imidazoline Receptor ligands with anti-inflammatory and neuroprotective activity, opening a new therapeutic approach for Alzheimer’s disease treatment. The compounds are characterized by presenting considerably less cardiovascular side-effects compared to existing ones. A pharmaceutical company interested in developing an Alzheimer’s disease drug is being sought for a licensing agreement.
The research team seeks pharmaceutical companies in all countries engaged in the development of Alzheimer’s disease drugs and interested in a license agreement. The company should be able to continue the development of the invention as well as to perform dose-response, toxicity and side effects studies.
Alzheimer’s disease is the largest unmet medical need in neurology. Existing drugs have scarce or limited efficacy and no new cognitive enhancer drugs are available currently. A new family of I2 Imidazoline Receptor ligands (compounds referred to as I2-IR ligands), selective against I2-IR and with potential less side-effects, has been developed by a research team composed by researchers from three Spanish Universities. The team has specialists in the area of synthesis of heterocyclic compounds with interest in the treatment of Alzheimer’s disease, neuropharmacology and neuropsychopharmacology. The new family of synthetic compounds developed relates to the field of compounds with high affinity for imidazoline receptors of the I2-type, which have been associated with prevention or treatment of human brain disorders, such as depression and Alzheimer’s disease, pain modulation, and inflammation. I2-IR are involved in physiologic processes related to analgesia, anti-inflammation and neuroprotection among others, which offers a wide range of applications for compounds targeting this type of proteins. It is also known that in Alzheimer’s disease brain patients the density (Bmax) of I2 imidazoline binding sites is significantly higher than in control samples, and that I2-IR ligands have neuroprotectant properties. In this regard, other I2-IR ligands have been developed and tested, but most of them show cardiac side-effects due to their activity upon α2-adrenergic receptors (α2-AR). Inspired in this rational, researchers focused their effort on developing compounds targeting selectively I2-IR; avoiding side-effects due to α2-AR activation and opening a new therapeutic approach for Alzheimer’s disease treatment. However, given the nature of I2-IR, other indications may also be targeted, such as osteoarthritis pain.
Advantages and innovations
- Potentially less cardiovascular side-effects. - A new therapeutic approach for Alzheimer’s disease treatment with anti-inflammatory and neuroprotective activity.
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below